T1	Condition 14 29	liver cirrhosis
T2	Condition 31 55	Hepatocellular Carcinoma
T3	Measurement 59 62	AFP
T4	Value 63 69	>2 ULN
T5	Condition 79 91	malignancies
*	OR T1 T2 T3 T5
R1	Has_value Arg1:T3 Arg2:T4	
T6	Condition 130 144	liver diseases
T7	Non-query-able 94 144	Patients with other factors causing liver diseases
T8	Pregnancy_considerations 147 175	Pregnant and lactating women
T9	Condition 204 217	HIV infection
T10	Qualifier 192 203	concomitant
R2	Has_qualifier Arg1:T9 Arg2:T10	
T11	Condition 221 258	congenital immune deficiency diseases
T12	Condition 275 283	diabetes
T13	Condition 285 304	autoimmune diseases
*	OR T9 T11
*	OR T13 T12
T14	Condition 331 349	organ dysfunctions
T15	Qualifier 321 330	important
R3	Has_qualifier Arg1:T14 Arg2:T15	
T16	Qualifier 366 373	serious
T17	Condition 374 387	complications
T18	Condition 395 404	infection
T19	Condition 406 428	hepatic encephalopathy
T20	Condition 430 450	hepatorenal syndrome
T21	Condition 452 477	gastrointestinal bleeding
*	OR T21 T20 T19 T18
T22	Scope 395 477	infection, hepatic encephalopathy, hepatorenal syndrome, gastrointestinal bleeding
R4	Has_qualifier Arg1:T17 Arg2:T16	
R5	Subsumes Arg1:T17 Arg2:T22	
T23	Procedure 502 516;537 544	antineoplastic therapy
T24	Procedure 520 544	immunomodulatory therapy
*	OR T24 T23
T25	Scope 502 544	antineoplastic or immunomodulatory therapy
T26	Temporal 552 566	past 12 months
R6	Has_temporal Arg1:T25 Arg2:T26	
T27	Drug 601 604	IFN
T28	Qualifier 605 627	anti hepatitis B virus
R7	Has_qualifier Arg1:T27 Arg2:T28	
T29	Condition 655 665	resistance
T30	Drug 646 654	NAs drug
R8	AND Arg1:T29 Arg2:T30	
*	OR T27 T29
T31	Post-eligibility 668 732	Patients who can't come back to clinic for follow-up on schedule
